Daniel Leung

Daniel Leung

Auto-generated profile, based on publicly available information

Daniel Leung

The University of Hong Kong

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MSMehul Sharma
Mehul Sharma
DLDaniel Leung
Daniel Leung
MMMana Momenilandi
Mana Momenilandi
LJLauren C.W. Jones
Lauren C.W. Jones
LPLucia Pacillo
Lucia Pacillo
STStuart E. Turvey
Stuart E. Turvey
STAT6 (signal transducer and activator of transcription 6) is a transcription factor that plays a central role in the pathophysiology of allergic inflammation. We have identified 16 patients from 10 families spanning three continents with a profound phenotype of early-life onset allergic immune dysregulation, widespread treatment-resistant atopic dermatitis, hypereosinophilia with esosinophilic gastrointestinal disease, asthma, elevated serum IgE, IgE-mediated food allergies, and anaphylaxis. The cases were either sporadic (seven kindreds) or followed an autosomal dominant inheritance pattern (three kindreds). All patients carried monoallelic rare variants in STAT6 and functional studies established their gain-of-function (GOF) phenotype with sustained STAT6 phosphorylation, increased STAT6 target gene expression, and TH2 skewing. Precision treatment with the anti–IL-4Rα antibody, dupilumab, was highly effective improving both clinical manifestations and immunological biomarkers. This study identifies heterozygous GOF variants in STAT6 as a novel autosomal dominant allergic disorder. We anticipate that our discovery of multiple kindreds with germline STAT6 GOF variants will facilitate the recognition of more affected individuals and the full definition of this new primary atopic disorder.

4 July 2022 in Emerging Microbes & Infections
Verified
Journal Article
Open access
WTWinnie Wan-Yee Tso
Winnie Wan-Yee Tso
MKMike Yat-Wah Kwan
Mike Yat-Wah Kwan
YWYu Liang Wang
Yu Liang Wang
LLLok Kan Leung
Lok Kan Leung
DLDaniel Leung
Daniel Leung
JDJaime S. Rosa Duque
Jaime S. Rosa Duque
There has been a rapid surge of hospitalization due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants globally. The severity of Omicron BA.2 in unexposed, unvaccinated, hospitalized children is unknown. We investigated the severity and clinical outcomes of COVID-19 infection during the Omicron wave in uninfected, unvaccinated hospitalized children and in comparison with influenza and parainfluenza viral infections. This population-based study retrieved data from the HK territory-wide CDARS database of hospitalisations in all public hospitals and compared severe outcomes for the Omicron BA.2-dominant fifth wave (5–28 February 2022, n = 1144), and influenza and parainfluenza viruses (1 January 2015–31 December 2019, n = 32212 and n = 16423, respectively) in children 0–11 years old. Two deaths (0.2%) out of 1144 cases during the initial Omicron wave were recorded. Twenty-one (1.8%) required PICU admission, and the relative risk was higher for Omicron than influenza virus (n = 254, 0.8%, adjusted RR = 2.1, 95%CI 1.3–3.3, p = 0.001). The proportion with neurological complications was 15.0% (n = 171) for Omicron, which was higher than influenza and parainfluenza viruses (n = 2707, 8.4%, adjusted RR = 1.6, 95%CI 1.4–1.9 and n = 1258, 7.7%, adjusted RR = 1.9, 95%CI 1.6–2.2, p < 0.001 for both, respectively). Croup occurred for Omicron (n = 61, 5.3%) more than influenza virus (n = 601, 1.9%, adjusted RR = 2.0, 95%CI 1.5–2.6, p < 0.001) but not parainfluenza virus (n = 889, 5.4%). Our findings showed that for hospitalized children who had no past COVID-19 or vaccination, Omicron BA.2 was not mild. Omicron BA.2 appeared to be more neuropathogenic than influenza and parainfluenza viruses. It targeted the upper airways more than influenza virus.

5 January 2023 in Communications Medicine
Verified
Journal Article
Open access
PDF file
DLDaniel Leung
Daniel Leung
JDJaime S. Rosa Duque
Jaime S. Rosa Duque
KYKa Man Yip
Ka Man Yip
Hung-kwan SoHung-kwan So
Hung-kwan So
WWWilfred Hing Sang Wong
Wilfred Hing Sang Wong
YLYu-Lung Lau
Yu-Lung Lau
Background: The SARS-CoV-2 Omicron BA.2 subvariant replaced BA.1 globally in early 2022, and caused an unprecedented tsunami of cases in Hong Kong, resulting in the collapse of elimination strategy. Vaccine effectiveness (VE) of BNT162b2 and CoronaVac against BA.2 is unclear. Methods: We utilize an ecological design incorporating population-level vaccine coverage statistics and territory-wide case-level SARS-CoV-2 infection surveillance data, and investigate the VE against infection during the Omicron BA.2 wave between January 1 to April 19, 2022, in Hong Kong for children and adolescents. Results: We estimate VE to be 33.0% for 1 dose of BNT162b2 in children aged 5–11 and 40.8% for 2 doses of CoronaVac in children aged 3–11. We also estimate 54.9% VE for 2 doses of BNT162b2, and 55.0% VE for 2 doses of CoronaVac in adolescents aged 12–18. Conclusions: Our findings support partly preserved VE against infection by variants of concerns for children and adolescents in settings with extremely low levels of prior SARS-CoV-2 circulation.

26 February 2022 in Kidney International
Verified
Journal Article
Closed access
AMAlison Lap-Tak Ma
Alison Lap-Tak Ma
DLDaniel Leung
Daniel Leung
ECEugene Yu-Hin Chan
Eugene Yu-Hin Chan
SCStella Chim
Stella Chim
SCSamuel Cheng
Samuel Cheng
YLYu-Lung Lau
Yu-Lung Lau

2 January 2023 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
MYMichael Kwan Leung Yu
Michael Kwan Leung Yu
SCSophelia Hoi Shan Chan
Sophelia Hoi Shan Chan
SCSamuel Cheng
Samuel Cheng
DLDaniel Leung
Daniel Leung
SCSau Man Chan
Sau Man Chan
JDJaime S Rosa Duque
Jaime S Rosa Duque
The mRNA-based BNT162b2 and inactivated whole-virus CoronaVac are two widely used COVID-19 vaccines that confer immune protection to healthy individuals. However, hesitancy toward COVID-19 vaccination appeared to be common for patients with neuromuscular diseases (NMDs) due to the paucity of data on the safety and efficacy in this high-risk patient population. Therefore, we examined the underlying factors associated with vaccine hesitancy across time for NMDs and assessed the reactogenicity and immunogenicity of these two vaccines. Patients aged 8–18 years with no cognitive delay were invited to complete surveys in January and April 2022. Patients aged 2–21 years were enrolled for COVID-19 vaccination between June 2021 and April 2022, and they recorded adverse reactions (ARs) for 7 days after vaccination. Peripheral blood was obtained before and within 49 days after vaccination to measure serological antibody responses compared to healthy children and adolescents. Forty-one patients completed vaccine hesitancy surveys for both timepoints, while 22 joined the reactogenicity and immunogenicity arm of the study. Two or more family members vaccinated against COVID-19 was positively associated with intention of vaccination (odds ratio 11.7, 95% CI 1.81–75.1, p = .010). Pain at the injection site, fatigue, and myalgia were the commonest ARs. Most ARs were mild (75.5%, n = 71/94). All 19 patients seroconverted against the wildtype SARS-CoV-2 after two doses of either vaccine, similar to 280 healthy counterparts. There was lower neutralization against the Omicron BA.1 variant. BNT162b2 and CoronaVac were safe and immunogenic for patients with NMDs, even in those on low-dose corticosteroids.

17 February 2022 in Pediatrics International
Verified
Journal Article
Open access
PDF file
THTimothy Keith Hung
Timothy Keith Hung
DLDaniel Leung
Daniel Leung
JDJaime S Rosa Duque
Jaime S Rosa Duque
YLYu-Lung Lau
Yu-Lung Lau
Click on the article title to read more.